Concepedia

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours

Stefano Severi, Oriana Nanni, Lisa Bodei, Maddalena Sansovini, Annarita Ianniello, Stefania Nicoletti, Emanuela Scarpi, Federica Matteucci, Laura Gilardi, Giovanni Paganelli

European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 143 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

, , +12

International Histological Classification of Tumours

RO Weller · Journal of Clinical Pathology · 1981 · 2K citations · Full text

, , +12

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

, , +17

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations

, , +15

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

Michael Gabriel, Clemens Decristoforo, Dorota Kendler et al. · Journal of Nuclear Medicine · 2007 · 1K citations · Full text

, , +17